Click here to view the presentation slides and transcript from this CME-certified series held at select College of American Pathologists (CAP) state chapter meetings. (coming soon)
Novel targeted therapies have transformed the outcomes of patients with NSCLC, and pathologists play a crucial role in assessing if patients are eligible for these targeted therapies. Community pathologists must be kept up to date with recommendations for pathologic testing to properly individualize treatments for NSCLC. There is also an increasing need to improve communication between the members of the multidisciplinary cancer care team to ensure the accurate diagnosis and management of NSCLC.
The Crucial Role of the Pathologist in the Multidisciplinary Care Team for NSCLC will provide community clinicians with the latest recommendations for pathological testing to guide personalized treatment selections in NSCLC, keep clinicians up to date with clinical practice guidelines, and provide them with the tools needed to engage their patients in treatment decisions.
I. Welcome and Introduction
II. Histologic and Molecular Testing
III. Clinical Case Discussions
- Lung adenocarcinoma with EGFR mutation
- Squamous cell lung carcinoma
- K-Ras-positive lung adenocarcinoma
IV. Questions and Discussion
This program is intended for community-based pathologists, oncologists, oncology nurses, pulmonologists, and other healthcare professionals involved in the care of patients with NSCLC.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Assess evidence-based biopsy and molecular testing methods for use in clinical practice
- Evaluate personalization of treatments of NSCLC based on molecular and immunologic biomarkers
- Understand the need for effective communication within the multidisciplinary team and with patients to formulate optimal treatment plans
Alain C. Borczuk, MD
Vice Chairman for Anatomic Pathology
Director of Anatomic Pathology
Chief of Thoracic Pathology
Weill Cornell Medicine
New York, NY
Alain C. Borczuk, MD is a graduate of NYC's Stuyvesant High School. After graduating Summa Cum Laude from Princeton University in the Department of Molecular Biology, he attended Cornell University Medical College, where he received his medical doctorate degree in 1991. He completed his internship in internal medicine at the New York Hospital, and completed his residency in anatomic pathology at the Albert Einstein College of Medicine. After serving as an attending pathologist at Jacobi Medical Center and North Shore University Hospital, he joined the Department of Pathology at Columbia University Medical Center in 1999. As a practicing pathologist, translational researcher, and active participant in the Pulmonary Program at Columbia, he achieved the rank of Professor of Pathology at Columbia University Medical College. He joined the faculty at Weill Cornell Medicine in 2015 as Vice Chairman and Director of Anatomic Pathology, as well as Chief of Thoracic Pathology.
Balazs Halmos, MD
Director, Thoracic Oncology and Clinical Cancer Genomics
Montefiore Medical Center/Albert Einstein College of Medicine
New York, NY
Balazs Halmos, MD is a thoracic oncologist specializing in the management of patients with malignancies of the thoracic cavity, such as lung and gastroesophageal cancers, as well as thymoma. He is Director of Thoracic Oncology and Director of Clinical Cancer Genomics at Montefiore Medical Center. Dr. Halmos also oversees the thoracic clinical trials program of novel clinical studies at the Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm to facilitate a personalized cancer medicine approach within the Montefiore Health System.
Dr. Halmos' research focus is on clinical studies of experimental therapeutics; in particular, studies of targeted agents for the treatment of thoracic malignancies and translational studies focused on different aspects of lung cancer biology, such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation, and targeted therapeutics.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.
There is no fee associated with this program.
Event staff will be glad to assist you with any specials needs. Please email email@example.com at least 5 days prior to the program.
Supported by independent educational grants from Genentech, Lilly, and Merck & Co., Inc.
|Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.